# A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)

> **NCT01076075** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 427 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Sitagliptin phosphate
- **DRUG:** Comparator: placebo to pioglitazone
- **DRUG:** Comparator: placebo to Sitagliptin
- **DRUG:** Comparator: pioglitazone
- **DRUG:** Glimepiride or gliclazide
- **DRUG:** Metformin
- **DRUG:** Pioglitazone rescue therapy

## Key facts

- **NCT ID:** NCT01076075
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06-03
- **Primary completion:** 2011-07-11
- **Final completion:** 2012-01-19
- **Target enrollment:** 427 (ACTUAL)
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076075

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076075, "A Study to Evaluate the Safety and Efficacy of Sitagliptin 100 mg in Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control (MK-0431-229)". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT01076075. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*